On Thursday, Kimberly Clark Corp (NYSE:KMB)’s shares declined -1.07% to $106.83.
Kimberly Clark Corp (KMB) In the first quarter, the firm’s sales in developing markets jumped 11%. Organic sales growth of diapers and feminine care products in those regions was in the teens and led Kimberly-Clark’s international performance, according to the company’s earnings report.
But international operations can be a double-edged sword, because the strong dollar bit into revenues.
Total Q1 sales fell 4% to $4.7 billion, as currency exchange rates reduced the top line by 9%. Kimberly-Clark anticipates currency headwinds to continue, although it has not changed its outlook. It has forecast full-year EPS of $5.60-$5.80, basically in line with analysts’ estimates.
Adjusted earnings in Q1 of $1.42 a share were up 8%, above expectations. Earnings growth historically has been dull, but it has been quite steady — a trait that favors income investors.
Kimberly-Clark Corporation, together with its auxiliaries, manufactures and markets personal care, consumer tissue, and K-C professional products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, Poise, and other brands.
Alkermes Plc (NASDAQ:ALKS)’s shares dropped -0.64% to $60.84.
Alkermes Plc (ALKS) declared that its corporate presentation will be webcast live at the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015, at 10:40 a.m. PDT (1:40 p.m. EDT/6:40 p.m. BST) from the Terranea Resort in Rancho Palos Verdes, Calif. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence.
At the end of Thursday’s trade, Ruckus Wireless Inc (NYSE:RKUS)‘s shares dipped -0.18% to $11.07.
Ruckus Wireless Inc (RKUS) declared that it is working with Smartac Group China Holdings Limited (Smartac) to assist build Ruckus Smart WiFi networks covering more than 300 passenger stations for three major railroad systems in China—Beijing, Guangzhou, and Lanzhou. The ongoing deployment is part of a long-term project to upgrade wireless networks across China’s vast passenger railway transportation system. These Ruckus Smart WiFi networks will not only provide a high-performance wireless Internet access experience for railway passengers, they will also provide comprehensive, real-time passenger data for railway station operators. The entire project is designed to make China’s railway passenger stations “Smart stations.” These new Smart stations are part of the emerging global trend to create Smart cities. The concept involves using state-of-the-art communications technology that improves municipal operations and services to enhance the way of life for residents and visitors of major urban centers.
Smartac Group is one of the most practiced ‘new-generation’ mobile Internet gateway providers in China. As one of the largest service providers of wireless networks for China’s railroad passenger stations, Smartac business comprises 379 of the busiest stations in two municipalities, Beijing and Tianjin. Smartac also provides network services to 11 other provinces and autonomous regions (Gansu, Guangdong, Guizhou, Hunan, Hubei, Hebei, Inner Mongolia, Ningxia, Shandong, Shaanxi, and Shanxi), serving 2 billion passengers a year.
Ruckus Wireless, Inc. provides carrier-class Wi-Fi solutions to service providers and enterprises worldwide. It provides gateways, controllers, and access points with related software and services. The company offers SmartCell, a line of carrier-grade wireless access and administration products that comprise specialized hardware products, such as SmartCell Gateways and SmartCell Access Points, in addition to software solutions comprising virtualized SmartCell Gateway and SmartCell Insight software platforms.
Hospira, Inc. (NYSE:HSP), ended its Thursday’s trading session with -0.09% loss, and closed at $88.37.
Hospira, Inc. (HSP) has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil. The medication will be marketed by Hospira. Hospira also markets and sells biosimilar infliximab in 26 European countries and in Canada under the brand name Inflectra. This important product has been approved in Brazil for the treatment of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s disease in adults and children, fistulizing Crohn’s disease (advanced), colitis and ulcerative rectocolitis.
Remsima is the first biological medication approved by Brazil’s regulator, ANVISA, based on comparability. A comparability study is required because under ANVISA’s Normative Resolution RDC 55/2010, biosimilarity must be proven by direct comparison with the reference biological drug (products must be contrast in a single clinical trial and using the same procedures). The study offered evidence of similarity between Remsima and the reference biological product, Remicade™ (infliximab).
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which comprise about 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
